Skip to content
Screener

Corvus Pharmaceuticals CRVS Q1 2026 earnings

Reported May 7, 2026 · After market close

EPS-$0.15Miss by $0.01
EPS estimate-$0.14

Next report

Nov 3, 2026 (in a month)
EPS estimate-$0.21

Financials

Q1 2026

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.23B+467%
Enterprise value$1.19B+459%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0×0.0×
Current ratio19.8×+14.9×

FAQ

When did Corvus Pharmaceuticals report Q1 2026 earnings?
Corvus Pharmaceuticals (CRVS) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Corvus Pharmaceuticals's Q1 2026 revenue and EPS?
Corvus Pharmaceuticals reported eps of $-0.15 for Q1 2026.
Did Corvus Pharmaceuticals beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.14 by $0.01.
How did Corvus Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 15.4% from $-0.13.
Where can I find Corvus Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-003154) and the 10-Q periodic report (0001104659-26-057100) directly on SEC EDGAR. The filing index links above go to sec.gov.